| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $999,999 ) |
| | 2023 | 2023 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R44DK125191 | Therapeutic antibodies for treating liver fibrosis | 000 | 3 | NIH | 8/29/2023 | $999,999 |
| | 2023 | 2020 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R43DK125191 | Therapeutic antibodies for treating liver fibrosis | 000 | 1 | NIH | 7/3/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,356,069 ) |
| | 2022 | 2022 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R44CA241513 | Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain | 000 | 3 | NIH | 4/18/2022 | $1,063,128 |
| | 2022 | 2022 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R44DK125191 | Therapeutic antibodies for treating liver fibrosis | 000 | 2 | NIH | 7/15/2022 | $999,999 |
| | 2022 | 2022 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R43HD106864 | Antibody agonist for a G protein-coupled receptor as a treatment for pain in endometriosis | 000 | 1 | NIH | 6/10/2022 | $292,942 |
| | 2022 | 2020 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R43DK125191 | Therapeutic antibodies for treating liver fibrosis | 002 | 1 | NIH | 8/29/2022 | $349,013 |
| | 2022 | 2020 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R43DK125191 | Therapeutic antibodies for treating liver fibrosis | 000 | 1 | NIH | 1/18/2022 | $0 |
| | 2022 | 2020 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R43DK125191 | Therapeutic antibodies for treating liver fibrosis | 001 | 1 | NIH | 7/22/2022 | -$349,013 |
| | 2022 | 2019 | ABALONE BIO, INC. | 1250 45TH ST STE 520 | EMERYVILLE | CA | 94608-2959 | ALAMEDA | USA | R43CA241513 | Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain | 000 | 1 | NIH | 12/6/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,216,114 ) |
| | 2021 | 2021 | ABALONE BIO, INC. | 2600 HILLTOP DR, BLDG B, RM C332 | RICHMOND | CA | 94806-1971 | CONTRA COSTA | USA | R43DK127654 | Therapeutic Antibodies for Treating Inflammatory Bowel Disease | 000 | 1 | NIH | 4/22/2021 | $300,241 |
| | 2021 | 2021 | ABALONE BIO, INC. | 2600 HILLTOP DR, BLDG B, RM C332 | RICHMOND | CA | 94806-1971 | CONTRA COSTA | USA | R44CA241513 | Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain | 000 | 2 | NIH | 5/4/2021 | $915,873 |
| | 2021 | 2020 | ABALONE BIO, INC. | 2600 HILLTOP DR, BLDG B, RM C332 | RICHMOND | CA | 94806-1971 | CONTRA COSTA | USA | R43DK125191 | Therapeutic antibodies for treating liver fibrosis | 000 | 1 | NIH | 6/16/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $349,013 ) |
| | 2020 | 2020 | ABALONE BIO, INC. | 2600 HILLTOP DR, BLDG B, RM C332 | RICHMOND | CA | 94806-1971 | CONTRA COSTA | USA | R43DK125191 | Therapeutic antibodies for treating liver fibrosis | 000 | 1 | NIH | 5/21/2020 | $349,013 |
|
| Issue Date FY: 2019 ( Subtotal = $299,999 ) |
| | 2019 | 2019 | ABALONE BIO, INC. | 2600 HILLTOP DR, BLDG B, RM C332 | RICHMOND | CA | 94806-1971 | CONTRA COSTA | USA | R43CA241513 | Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain | 000 | 1 | NIH | 9/25/2019 | $299,999 |
|
|
